文献速递膀胱癌与上尿路尿路上皮癌

非尿路上皮变异组织学对根治性膀胱切除术后肿瘤学结局的影响

The impact of non-urothelial variant histology on oncological outcomes following radical cystectomy.
PubMed 文献 · BJU Int · 2019-03-04

该研究回顾性分析2010年1月至2017年1月在一家高容量区域三级膀胱癌服务中心接受根治性膀胱切除术的430例患者,其中73例(17%)为非尿路上皮变异组织学(NUVH),357例(83%)为纯尿路上皮癌(PUC)。多因素分析显示NUVH与总死亡率、膀胱癌特异性死亡率和疾病复发风险升高相关,鳞状细胞变异亚型同样与不良结局相关。作者认为NUVH是较差结局的独立预测因素,术前应告知患者术后结局较差及可能需要辅助治疗。

要点

  • NUVH患者根治性膀胱切除术后总死亡率(HR 1.86)、膀胱癌特异性死亡率(HR 1.81)和复发风险(HR 1.71)均升高。
  • 鳞状细胞变异亚型与总死亡率(HR 1.91)、癌症特异性死亡率(HR 2.03)和复发(HR 2.08)升高相关。
  • NUVH与淋巴结阳性在多因素分析中无显著关联(HR 1.28,95%CI 0.59-2.75),但与更晚期肿瘤分期相关(P<0.001)。

核心结论

  • 与纯尿路上皮癌相比,非尿路上皮变异组织学与更短生存相关,提示其是较差结局的独立预测因素。
  • 作者建议术前告知NUVH患者术后总体和疾病特异性结局较差,以及可能需要辅助治疗。

研究设计与样本

  • 回顾性分析2010年1月至2017年1月在一家高容量区域三级膀胱癌服务中心前瞻性维护的数据库,纳入所有接受根治性膀胱切除术的患者。
  • 共430例患者接受根治性膀胱切除术,其中73例(17%)有NUVH,357例(83%)为PUC。
  • 中位(范围)随访时间为45.0(8.5-100.2)个月。
  • 采用多因素Cox比例风险回归分析确定疾病复发、总生存和膀胱癌特异性生存以及淋巴结阳性,采用卡方分析确定肿瘤分期的关联。

主要发现

  • 多因素分析中,NUVH与总死亡率升高相关(HR 1.86,95%CI 1.21-2.85)。
  • 多因素分析中,NUVH与膀胱癌特异性死亡率升高相关(HR 1.81,95%CI 1.91-3.01)。
  • 多因素分析中,NUVH与疾病复发风险升高相关(HR 1.71,95%CI 1.06-2.75)。
  • 鳞状细胞变异与总死亡率升高(HR 1.91,95%CI 1.16-3.13)、癌症特异性死亡率升高(HR 2.03,95%CI 1.21-3.42)和疾病复发风险升高(HR 2.08,95%CI 1.23-3.52)相关,其他变异亚型未见此关联。
  • 多因素分析中淋巴结阳性与NUVH无显著关联(HR 1.28,95%CI 0.59-2.75),但卡方分析显示NUVH与更晚期肿瘤分期相关(P<0.001)。

临床怎么用

  • 作者认为NUVH是较差结局的独立预测因素,术前应告知NUVH患者术后总体和疾病特异性结局较差,以及可能需要辅助治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if the presence of non-urothelial variant histology (NUVH) is associated with a poorer prognosis following radical cystectomy (RC) compared to pure urothelial carcinoma (PUC). PATIENTS AND METHODS: A prospectively maintained database of all patients undergoing RC at a high-volume regional tertiary bladder cancer service between January 2010 and January 2017 was retrospectively analysed looking for patients with NUVH. Multivariate Cox proportional hazards regression analysis was used to determine disease recurrence, overall survival and bladder cancer-specific survival, as well as lymph node positivity. Association of tumour stage was determined using chi-squared analysis. RESULTS: In total, 430 patients underwent RC of which 73 (17%) had NUVH and 357 (83%) had PUC. The median (range) follow-up was 45.0 (8.5-100.2) months. The presence of NUVH was associated with both increased overall (hazard ratio [HR] 1.86, 95% confidence interval [CI] 1.21-2.85) and bladder cancer-specific mortality (HR 1.81, 95% CI 1.91-3.01), as well as disease recurrence (HR 1.71, 95% CI 1.06-2.75) in multivariate analysis. Squamous cell variant was also associated with increased overall mortality (HR 1.91, 95% CI 1.16-3.13), cancer-specific mortality (HR 2.03, 95% CI 1.21-3.42) and disease recurrence (HR 2.08, 95% CI 1.23-3.52), although this was not seen in other variant subtypes. Lymph node positivity was not associated with NUVH in multivariate analysis (HR 1.28, 95% CI 0.59-2.75), but NUVH was associated with advanced tumour stage on chi-squared analysis (P < 0.001). CONCLUSION: Our results showed a risk of shorter survival in NUVH compared to PUC. This suggests NUVH as an independent predictor of worse outcomes. As a result, patients with NUVH should be counselled preoperatively that overall and disease-specific outcomes are worse postoperatively and about the possible need for adjuvant treatment.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Stroman L, Nair R, Russell B, et al. The impact of non-urothelial variant histology on oncological outcomes following radical cystectomy. BJU Int. 2019. PMID: 30740862. doi:10.1111/bju.14704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。